Literature DB >> 24611884

Carnitine deficiency is associated with late-onset hypogonadism and depression in uremic men with hemodialysis.

Kei Fukami1, Sho-ichi Yamagishi, Kazuko Sakai, Yusuke Kaida, Aki Minami, Yosuke Nakayama, Ryotaro Ando, Nana Obara, Seiji Ueda, Yoshifumi Wada, Seiya Okuda.   

Abstract

Late-onset hypogonadism (LOH) and depression contribute to cardiovascular disease (CVD) in male hemodialysis (HD) patients. Carnitine deficiency is frequently observed in HD patients, playing a role in CVD. We examined whether carnitine deficiency was independently associated with LOH and depression in these patients. Twenty-six male HD patients underwent determinations of serum levels of free carnitine and testosterone. Status of LOH and depression were evaluated by questionnaires using aging male symptoms' (AMS) scale and self-rating depression scale (SDS), respectively. Free carnitine and testosterone levels in male HD patients were significantly lower than those in age-matched healthy male subjects. Linear regression analysis showed that AMS scale was positively associated with SDS. Univariate regression analysis revealed that total carnitine (inversely), free carnitine (inversely) and HD duration were correlated with AMS scale. Multiple stepwise regression analysis revealed that free carnitine was an independent determinant of AMS scale. Furthermore, free carnitine was also independently correlated with SDS in male HD patients. This study demonstrated that decreased free carnitine levels were independently associated with AMS scale and SDS in male HD patients. The observations suggest that decreased free carnitine levels could be a marker and therapeutic target of LOH and depression in uremic men with HD.

Entities:  

Keywords:  AMS scale; SDS; carnitine deficiency; depression; hemodialysis; late-onset hypogonadism

Mesh:

Substances:

Year:  2014        PMID: 24611884     DOI: 10.3109/13685538.2014.888053

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  6 in total

1.  Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.

Authors:  Ahmed T Ahmed; Siamak MahmoudianDehkordi; Sudeepa Bhattacharyya; Matthias Arnold; Duan Liu; Drew Neavin; M Arthur Moseley; J Will Thompson; Lisa St John Williams; Gregory Louie; Michelle K Skime; Liewei Wang; Patricio Riva-Posse; William M McDonald; William V Bobo; W Edward Craighead; Ranga Krishnan; Richard M Weinshilboum; Boadie W Dunlop; David S Millington; A John Rush; Mark A Frye; Rima Kaddurah-Daouk
Journal:  J Affect Disord       Date:  2019-11-30       Impact factor: 4.839

2.  The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study.

Authors:  Mustafa Alwani; Raed M Al-Zoubi; Ahmad Al-Qudimat; Aksam Yassin; Omar Aboumarzouk; Khaled Al-Rumaihi; Raidh Talib; Abdulla Al-Ansari
Journal:  Ann Med Surg (Lond)       Date:  2021-08-23

3.  Plasma Metabolomics Profile of "Insulin Sensitive" Male Hypogonadism after Testosterone Replacement Therapy.

Authors:  Lello Zolla; Marcello Ceci
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 5.923

Review 4.  Carnitine and Depression.

Authors:  Ting Liu; Kunhong Deng; Ying Xue; Rui Yang; Rong Yang; Zhicheng Gong; Mimi Tang
Journal:  Front Nutr       Date:  2022-03-14

5.  L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study.

Authors:  Jie V Zhao; Stephen Burgess; Bohan Fan; C Mary Schooling
Journal:  BMC Med       Date:  2022-09-01       Impact factor: 11.150

6.  L-Carnitine Supplementation Improves Self-Rating Depression Scale Scores in Uremic Male Patients Undergoing Hemodialysis.

Authors:  Kyoko Tashiro; Yusuke Kaida; Sho-Ichi Yamagishi; Hideharu Tanaka; Miyuki Yokoro; Junko Yano; Kazuko Sakai; Yuka Kurokawa; Kensei Taguchi; Yosuke Nakayama; Takahiro Inokuchi; Kei Fukami
Journal:  Lett Drug Des Discov       Date:  2017-06       Impact factor: 1.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.